Merkel cell carcinoma: Correlation of KIT expression with survival and evaluation of KIT gene mutational status

Human Pathology

Volumn 41, Issue 10, 2010, Pages 1405-1412

  Andea, Aleodor A ^a   Patel, Raj ^a   Ponnazhagan, Selvarangan ^a   Kumar, Sanjay ^a   Devilliers, Patricia ^a   Jhala, Darshana ^a   Eltoum, Isam E ^a   Siegal, Gene P ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

c kit; KIT; Merkel cell carcinoma; Neuroendocrine

Indexed keywords

STEM CELL FACTOR; TYROSINE KINASE RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MERKEL CELL; MERKEL CELL TUMOR; BIOSYNTHESIS; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; POINT MUTATION; SKIN TUMOR; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MERKEL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 77957164870     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.02.010     Document Type: Article

References (41)

1. Toker C. Trabecular carcinoma of the skin Arch Dermatol 105 1972 107 110
2. Tang C.K, and Toker C. Trabecular carcinoma of the skin: an ultrastructural study Cancer 42 1978 2311 2321
3. Agelli M, and Clegg L.X. Epidemiology of primary Merkel cell carcinoma in the united states J Am Acad Dermatol 49 2003 832 841
4. Hodgson N.C. Merkel cell carcinoma: changing incidence trends J Surg Oncol 89 2005 1 4
5. Allen P.J, Bowne W.B, Jaques D.P, Brennan M.F, Busam K, and Coit D.G. Merkel cell carcinoma: prognosis and treatment of patients from a single institution J Clin Oncol 23 2005 2300 2309
6. Allen P.J, Zhang Z.F, and Coit D.G. Surgical management of Merkel cell carcinoma Ann Surg 229 1999 97 105
7. Andea A.A, Coit D.G, Amin B, and Busam K.J. Merkel cell carcinoma: histologic features and prognosis Cancer 113 2008 2549 2558
8. Eng T.Y, Naguib M, Fuller C.D, Jones W.E. III , and Herman T.S. Treatment of recurrent Merkel cell carcinoma: an analysis of 46 cases Am J Clin Oncol 27 2004 576 583
9. Koljonen V, Bohling T, Granhroth G, and Tukiainen E. Merkel cell carcinoma: a clinicopathological study of 34 patients Eur J Surg Oncol 29 2003 607 610
10. Medina-Franco H, Urist M.M, Fiveash J, Heslin M.J, Bland K.I, and Beenken S.W. Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases Ann Surg Oncol 8 2001 204 208
11. Yiengpruksawan A, Coit D.G, Thaler H.T, Urmacher C, and Knapper W.K. Merkel cell carcinoma. Prognosis and management Arch Surg 126 1991 1514 1519
12. Tai P.T, Yu E, Tonita J, and Gilchrist J. Merkel cell carcinoma of the skin J Cutan Med Surg 4 2000 186 195
13. Ratner D, Nelson B.R, Brown M.D, and Johnson T.M. Merkel cell carcinoma J Am Acad Dermatol 29 1993 143 156
14. Haag M.L, Glass L.F, and Fenske N.A. Merkel cell carcinoma. Diagnosis and treatment Dermatol Surg 21 1995 669 683
15. Hitchcock C.L, Bland K.I, Laney R.G. III , Franzini D, Harris B, and Copeland E.M. III Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment Ann Surg 207 1988 201 207
16. Cotlar A.M, Gates J.O, and Gibbs F.A. Jr Merkel cell carcinoma: combined surgery and radiation therapy Am Surg 52 1986 159 164
17. Eich H.T, Eich D, and Staar S. Role of postoperative radiotherapy in the management of Merkel cell carcinoma Am J Clin Oncol 25 2002 50 56
18. Su L.D, Fullen D.R, Lowe L, Uherova P, Schnitzer B, and Valdez R. Cd117 (kit receptor) expression in Merkel cell carcinoma Am J Dermatopathol 24 2002 289 293
19. Strong S, Shalders K, Carr R, and Snead D.R. Kit receptor (cd117) expression in Merkel cell carcinoma Br J Dermatol 150 2004 384 385
20. Yang D.T, Holden J.A, and Florell S.R. Cd117, ck20, ttf-1, and DNA topoisomerase ii-alpha antigen expression in small cell tumors J Cutan Pathol 31 2004 254 261
21. Feinmesser M, Halpern M, and Kaganovsky E. C-kit expression in primary and metastatic Merkel cell carcinoma Am J Dermatopathol 26 2004 458 462
22. Swick B.L, Ravdel L, Fitzpatrick J.E, and Robinson W.A. Merkel cell carcinoma: evaluation of kit (cd117) expression and failure to demonstrate activating mutations in the c-kit proto-oncogene-implications for treatment with imatinib mesylate J Cutan Pathol 34 2007 324 329
23. Brunner M, Thurnher D, and Pammer J. Expression of vegf-a/c, vegf-r2, pdgf-alpha/beta, c-kit, egfr, her-2/neu, mcl-1 and bmi-1 in Merkel cell carcinoma Mod Pathol 21 2008 876 884
24. Kartha R.V, and Sundram U.N. Silent mutations in kit and pdgfra and coexpression of receptors with scf and pdgfa in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis Mod Pathol 21 2008 96 104
25. Krasagakis K, Kruger-Krasagakis S, Eberle J, Tsatsakis A, Tosca A.D, and Stathopoulos E.N. Co-expression of kit receptor and its ligand stem cell factor in Merkel cell carcinoma Dermatology (Basel, Switzerland) 218 2009 37 43
26. Yang Q, Hornick J.L, Granter S.R, and Wang L.C. Merkel cell carcinoma: lack of kit positivity and implications for the use of imatinib mesylate Appl Immunohistochem Mol Morphol 17 2009 276 281
27. Blume-Jensen P, and Hunter T. Oncogenic kinase signalling Nature 411 2001 355 365
28. Taniguchi M, Nishida T, and Hirota S. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors Cancer Res 59 1999 4297 4300
29. Hirota S, Isozaki K, and Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577 580 (Pubitemid 28067289)
30. Antonescu C.R, Besmer P, and Guo T. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 2005 4182 4190
31. Antonescu C.R, Sommer G, and Sarran L. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors Clin Cancer Res 9 2003 3329 3337
32. Curtin J.A, Busam K, Pinkel D, and Bastian B.C. Somatic activation of kit in distinct subtypes of melanoma J Clin Oncol 24 2006 4340 4346
33. Hodi F.S, Friedlander P, and Corless C.L. Major response to imatinib mesylate in kit-mutated melanoma J Clin Oncol 26 2008 2046 2051
34. Fiorentini G, Rossi S, and Lanzanova G. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunohistochemical c-kit (cd 117): preliminary results of a compassionate use clinical trial J Exp Clin Cancer Res 22 2003 17 20
35. Llombart B, Sanmartin O, and Lopez-Guerrero J.A. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (col1a1-pdgfb) study with therapeutic implications Histopathology 54 2009 860 872
36. Flicek P, Aken B.L, and Beal K. Ensembl 2008 Nucleic Acids Res 36 2008 D707 D714
37. Agaram N.P, Besmer P, and Wong G.C. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors Clin Cancer Res 13 2007 170 181
38. Rozen S, and Skaletsky H. Primer3 on the WWW for general users and for biologist programmers Methods Mol Biol (Clifton, NJ) 132 2000 365 386
39. Llombart B, Monteagudo C, and Lopez-Guerrero J.A. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers Histopathology 46 2005 622 634
40. Lasota J, Corless C.L, and Heinrich M.C. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary kit exon 13 or exon 17 mutations: a multicenter study on 54 cases Mod Pathol 21 2008 476 484
41. Prakash S, Sarran L, and Socci N. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature J Pediatr Hematol Oncol 27 2005 179 187